How did IKNA's revenue trends shift in Q4 2024?

Ikena Oncology, Inc. (IKNA) experienced a significant decline in revenue in Q4 2024 compared to the previous quarter.

1. **Revenue Decline**: The company's revenue in Q4 2024 was not reported, but the latest available data is from Q3 2024, where the net loss was $8.6 million. This indicates a financial strain during that period.

2. **Financial Strain**: The net loss per share was $(0.18), an improvement from $(0.33) in the prior year, but the total operating expenses were $10.8 million, a 41% decrease compared to the prior year. This suggests that while there is a reduction in losses, the company is still facing financial challenges.
3. **Strategic Changes**: Ikena Oncology has been focusing on cost management and strategic realignment, which includes reducing research and development expenses and workforce restructuring. These changes may have impacted the revenue figures, as the company prioritized streamlining its operations over revenue generation in this period.

In conclusion, IKNA's revenue trends in Q4 2024 were marked by a significant decline, reflecting the company's financial challenges and strategic shifts aimed at cost management and realignment.